Back

Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials

27 August 2021 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Peripheral Vascular and Cerebrovascular Disease ePosters Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Wolfgang Koenig

TUM Universitätsklinikum, German Heart Center, Munich (Germany)

18 More presentations in this session

Presentation thumbnail
Impact of polyvascular disease on the prognosis of acute coronary syndrome
Professor N. Laraba (Algiers, DZ)
Abstract Slides
Presentation thumbnail
The efficacy and safety of dual-pathway inhibition therapy among patients with peripheral arterial disease - a meta-analysis
Doctor J. Mapili (Manila, PH)
Abstract Slides
Presentation thumbnail
Total thrombus-formation analysis system (T-TAS) can predict target lesion revascularization in patients undergoing endovascular therapy for critical limb ischemia
Doctor N. Kuyama (Osaka, JP)
Abstract Slides
Presentation thumbnail
Temporal course of vascular response after fluoropolymer paclitaxel-eluting stent implantation for femoropopliteal artery lesions
Doctor Y. Tomoi (Kitakyushu, JP)
Abstract Slides
Presentation thumbnail
Pre-dilatation prior to carotid artery stenting in very severe carotid artery stenosis: beneficial or detrimental?
Doctor M. Keskin (Istanbul, TR)
Abstract Slides

Access the full session

Session thumbnail
Peripheral Vascular and Cerebrovascular Disease ePosters

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials
30 August 2021
thumbnail
Congress Session
Cardio-metabolic aspects of stroke and cerebrovascular disease
24 April 2026
thumbnail
Congress Presentation
The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe
28 August 2022
thumbnail
Congress Presentation
Baseline triglycerides and non-HDL-C and apoB goal attainment in the ORION-10 and ORION-11 trials
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources